CARDIOLOGY Flashcards
sss
Absolute CVD Risk assessment
Target groups—?
all adults ≥ 45 years without known history of CVD
*ATSIP ≥ 35 years
(Aboriginal and Torres Strait Islander Partnerships)
Aboriginal and Torres Strait Islander Partnerships
Absolute CVD Risk assessment
Specific screening recommendations:
BP?
fasting blood lipids?
diabetes?
kideney disease?
*BP should be measured in all adults from age 18 years at least every 2 years.
*Adults should have their **fasting blood lipids **assessed starting at age 45 years, every 5 years (ATSIP: 35 years).
*Adults should be screened for diabetes(fasting plasma glucose) every 3 years from age 40 years (ATSIP: from 18 years).
*Adults at high risk should be screened for kidney disease every 1–2 years (ACR ratio and eGFR).
Dyslipidemia
Low HDL-C (<1.0 mmol/L) with high triglycerides
first line of therapy in EVERY LEVEL?
NON PHARMACOLOGICAL MEASSURES - life style changes - reacces after 6-8 *weeks
excersice
no smoking
no alcohol
weight reduction
Secondary HTN :
TRACKPADS
TRACKPADS
Thyroid disease (hyper-)
Renovascular disease (renal artery stenosis)
Aorta, coarctation of
Cushing syndrome
Kidney disease, chronic
Pheochromocytoma -headache, sweating, tachycardia
Aldosteronism (hyper-) = Conn’s syndrome -Triad of HTN, unexplained hypokalemia, metabolic alkalosis
Drugs (e.g. OCPs, decongestants, NSAIDS)
Sleep apnoea
Isolated systolic HTN
≥ 140 mmHg in the presence of a diastolic pressure <90 mmHg. Seen in elderly
Refractory hypertension :
BP >140/90 mmHg despite maximum dosage of two drugs for 3–4 month
Classification of HTN
remember to use the high value to classify
Treatment strategy for patients with newly diagnosed HTN
HTN
first line of TX
- Initial monotherapy
Angiotensin-converting enzyme inhibitor
First line management
Drug of choice in CKD with normal GFR
Angiotensin-converting enzyme inhibitor
side effects:
Side effects:
Cough**
**Hyperkalaemia(risk increased by renal impairment)
Renal** impairment (risk increased by hypovolaemia or NSAIDs)
**Angioedema (infrequent; may occur after years of treatment)
second category HTN tx
and side effects
Angiotensinreceptor blocker (Sartans)
*Hyperkalaemia (risk increased by renal impairment)
*Renal impairment (risk increased by hypovolaemia or NSAIDs)
*Cough and angioedema are rare
3th line of treatment side effects
Dihydropyridine (Amlodipine, nifedipine)
*Minimal effect on myocardial contractility and cardiac conduction.
*Do not treat calcium channel blocker induced peripheral oedema with diuretics.
Side effects: Peripheral vasodilation (peripheral oedema, flushing, headache, dizziness), postural hypotension, tachycardia, palpitations, chest pain, gingival hyperplasia
**Nondyhidropyridine(Verapamil, diltiazem)
**
*Less peripheral vasodilation than dihydropyridines.
*Reduce heart rate and depress cardiac contractility (verapamil more than diltiazem).
*Side effects: Bradycardia, constipation (particularly verapamil, may be severe), atrioventricular block, heart failure.
4th tx HTN
Thiazide diuretic:
may be preferred over an ACE inhibitor, ARB, or dihydropyridine calcium channel blocker in patients with:
suggest treating with a thiazide-like diuretic (ie,chlorthalidone,indapamide) rather thanhydrochlorothiazide
edema, osteoporosis, or calcium nephrolithiasis with hypercalciuria
Thiazide diuretic:
side effects:
Side effects: Postural hypotension, dizziness, hypokalaemia, hyponatraemia, hyperuricaemia, hyperglycaemia
HTN TX
5TH LINE
Beta blockers
Side-effects:
Side-effects: Bradycardia, postural hypotension, worsening of heart failure (transient), bronchospasm, cold extremities
HTN TX
5TH LINE
Beta blockers
CONTRAINDICATIONS
severe bradycardia
*preexistingsick sinus syndrome,
*second-and third-degree atrioventricular block
*severe left ventricular dysfunction
*fluid overload
*Ractive peripheral vascular diseasewith restischemia,
*reactive airway diseaseso severe that airway support is required -Asthma
*hypotension
HTN TX IN SPECIFIC POPULATION
BP TX TARGETS
Hypertensive urgency
definition
Hypertensive Crisis
severe HTN (>180/110 mmhg) patients who are not experiencing acute end-organ damage
usually oral HTN with aim to reduce over 24 h
Hypertensive emergency
definition
severe HTN (>220 /> 140 mmHg) with evidence of acute end-organ damage
Chest pain (ischemia/MI), Back pain (aortic dissection), Altered mental status (encaphalopathy), renal disease
Hypertensive emergency
TX
Life-threatening and require immediate treatment, usually with parenteral medications (labetalol, nitroprusside, nicardipine) in a monitored setting
Aim to reduce the BP by no more than 25% within the first 2 hours to prevent cerebral hypoperfusion or coronary insufficiency -> then towards 160/100 mmHg within 2 to 6 hours.
Malignant HTN
definition
DBP> 120 mmHG and exudative vasculopathy in the retinal and kidney circulations
renal artery stenosis HTN
age and etiology
Common in patients <25yrs and >50yrs with recent onset HTN
**Fibromuscular dysplasia **in younger pts
atherosclerosis (MCC) in older pts
renal artery stenosis
MX
Initial inv for **stable cases **-Doppler Duplex USG
*Initial inv for unstablecases -CT angio
renal artery stenosis
TX
Start 1stline ACE inhib/ARB
2ndline CCB
Percutaneous renal artery angioplasty for recurrence/refractory/PE
*Reduce hypercholesterolemia with Statins
*Diuretics NOT recommended
- ACEI is considered in unilateral cases. In bilateral cases, ACEIs can accelerate kidney failure by preferential vasodilation of the efferent arteriole
Pheochromocytoma
Symptoms
Episodic headache, sweating/diaphoresis, palpitations/paroxysmal tachycardia
Pheochromocytoma
investigation of choice
BEST = 24hr urinary metanephrines and catecholamine levels
or
Plasma metanephrines
Pheochromocytoma
TX
First give Alpha blockers to control HTN
*Next give BB to control tachycardia. (never give BB first as unopposed alpha-adrenergic stimulation will lead to refractory HTN)
refractory=
*Surgical resection
Conn’s Syndrome/Hyperaldosteronism
Diagnosis TRIAD
Excessive secretion of aldosterone from zona glomerulosa of adrenal cortex.
HTN,
unexplained hypokalemia,
metabolic alkalosis
Mild hypernatremia
*Hypomagnesemia
*Inc Plasma aldosterone, Dec Renin level and Inc aldosterone/renin ratio
coronary artery disease 4 types: flow chart
Angina Pectoris (Stable Angina)
definition
Retrosternal chest discomfort (pain or tightness) that lasts **10 minutes **or less and subsides promptly with rest.
it occurs when myocardial oxygen demand exceeds supply, which is usually restricted by athero
most common are shortness of breath, nausea, and diaphoresis
Angina Pectoris (Stable Angina)
mx
ST segment changes on exercise stress test with ECG monitoring*
Troponin -They are unlikely to be elevated in patients with intermittent and relatively brief angina episodes. However, they may be useful when the anginal episode is more prolonged and for prognostication
Prinzmetal Angina
definition
popultation
Prinzmetal’s (variant) angina mimics angina pectoris but is caused by vasospasm of coronary vessels.
It classically effects young women at rest in the early morning and is associated with ST-segment elevation in the absence of cardiac enzyme elevation.
The typical patient is a female smoker
Prinzmetal Angina
vs
angina estable
activity:
symptoms:
akg and no symptoms”:
ekg and symptoms:
cath findings:
treatment:
Prinzmetal Angina
TX
These episodes tend to self-resolve; however, cardiac-selective calcium channel blockers such as verapamil or diltiazem
CARDIAC SELECTIVE
NIFEDIPINE
Angina Pectoris
Tx for Episodes of Angina:
Glyceryl trinitrate
Before taking glyceryl trinitrate, they should sit down, to avoid orthos
Glyceryl trinitrate spray 400 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated angina, treatmentORGlyceryl trinitrate tablet 300 to 600 micrograms sublingually, repeat every 5 minutes if pain persists, up to a total of 3 doses if tolerated.
Action plan for pre-hospital angina:
**Rest + nitrate
*Aspirinif no CI
*call ambulance if pain doesn’t subside in 10 min**
Angina Pectoris TX Prevention of Angina:
Combo of 2 antianginal drugs
- ***Short-acting glyceryl trinitrate **can be taken before exercise that is likely to provoke angina
- *Beta blockers(atenolol, metoprolol tartare) enhance exercise tolerance by reducing myocardial oxygen demand. In LV dysfunction use these BB instead Carvedilol, bisoprolol, nebivolol or metoprolol succinate
- Nondihydropyridine CCB (diltiazem, verapamil) reduce heart rate and can be used as an alternative if beta-blocker therapy is contraindicatedor not tolerated
Do not use BB and diltiazem/Verapamil NOT = severe bradycardia and heart failure!!!
. *Avoidusing diltiazem or verapamil for patients with left ventricular dysfunction (LVEF <40%)
- dihydropyridine calcium channel blocker(amlodipine, modified-release nifedipine) can be added to a beta blocker if angina persists
- **Long-acting nitrate **(transdermal glyceryl trinitrate, modified-release isosorbide mononitrate) can be added either to a beta blocker, or to a nondihydropyridinecalcium channel blocker (diltiazem, verapamil)
- Nicorandilis an option for patients with refractory angina despite optimal therapy with the preceding drugs. Add to beta-blocker, diltiazem or verapamil therapy
atenolol 25 mg orally, daily, increasing if required up to 100 mg daily
OR
metoprolol tartrate 25 mg orally, twice daily, increasing if required up to 100 mg twice daily
ACUTE CORONARY SYNDROME
Typical presentation
Typical presentation
crushing or heavy central chest pain that may radiate to the arms, neck, back and jaw. Left arm pain is common, but bilateral or right arm pain are more specific.
An acute coronary syndrome may be associated with shortness of breath, nausea and sweating
ACUTE CORONARY SYNDROME
Atypical presentation
*burning pain, pain that increases with respiration, sharp pain (patients sometimes say ‘sharp’ when they mean ‘severe’ pain)
*upper abdominal pain.
Pain may also be absent (‘silent’ acute myocardial infarction). In particular, consider an acute coronary syndrome in patients with *diabetes and older patients who have no pain but do have associated symptoms (egshortness of breath, nausea, sweating), or poorly controlled diabetes.
ACUTE CORONARY SYNDROME
When to suspect ACS:
Rest angina, which is usually more than 20 minutes in duration
*New onset angina that markedly limits physical activity
*Increasing angina that is more frequent, longer in duration, or occurs with less exertion than previous angina
Acute coronary syndromes result from unstable atherosclerotic plaques or endothelial disruption, with associated transient or permanent thrombotic occlusion of the coronary arteries, leading to myocardial infarction and ischaemia
Classification based on ST elevation
**1. ST elevation myocardial infarction (STEMI)—a medical emergency
*According to guidelines, to diagnose Acute STEMI. Patient should have chest pain/discomfort suggestive of AMI in the presence of ST elevation more than 1mm in two contagious leads , or a newly developed LBBB.
- Non–ST elevation acute coronary syndrome (NSTEACS)—the initial description for patients without ST elevation. Subsequent investigation divides NSTEACS into:
** A)** Non–ST elevation myocardial infarction (NSTEMI)—patients with MI as determined by elevated cardiac biomarkers
** B)**Unstable angina—patients without elevated cardiac biomarkers. It signals impending infarction.
NSTEACS can progress to STEMI; ongoing monitoring is essential
Universal classification of MI
Type 1 spontaneous MI -atherothrombotic coronary occlusion
Type 2 MI -is secondary to ischaemic imbalance
tachyarrhythmias, bradyarrhythmias, anaemia, respiratory failure and hypotension
assesmment INV of acute chest pain
- ECG -12 leads WITHIN 10 MIN of arrival to ER
normal does not rule out IM -
TROPONINE
**Repeat Troponin levels after every 3-4hrs
OTHER CAUSES OF TROPONIN ELEVATION
ECG leads & area of STEMI
Mx during initial assessment
Mx of confirmed STEMI
A) Percutaneous coronary intervention
or
B)fibrinolytic therapy.
Consider all patients with a STEMI for admission to a coronary care unit for monitoring and expert acute care
Started within the 12 hours preceding presentation
Mx meds in confirmed STEMI
Dual antiplatelet therapy for STEMI -
1) with aspirin
2) P2Y12 inhibitor (clopidogrel, prasugrel, ticagrelor)
For a patient receiving fibrinolytic therapy, give with aspirin CLOPIDOGREL!
Reperfusion therapy
time?
PCI is available within 90 minutes of first medical contact, PCI is preferred over fibrinolytic therapy.
2.If PCI cannot be delivered promptly, fibrinolytic therapy should be given within 30 minutes of the patient arriving at the hospital.
.3 PCI is not available, and fibrinolytic therapy is not an option for them, then** promptly transfer them to a centrewhere PCI is available**.
In some healthcare services, paramedics can give fibrinolytic therapy before the patient reaches hospital
Percutaneous coronary intervention
(transluminal coronary balloon angioplasty and stenting)
complication + tx
nsignificant CAD is defined as stenosis <50% and does not often require intervention.*Significant stenosis
**(>50%) may be considered for ballooning, atherectomy, stenting****
Psuedoaneurysmat the site of insertion is a complication of PCI. It is a haematoma with communication to the artery (iliac/femoral/peroneal) that appears as a pulsatile painful mass in groin. It is treated by USG guided thrombin injection away from the neck of sac
PIC
adjuvant medication
Adjuvant drug therapy:*
dual antiplatelet therapy—aspirin + P2Y12 inhibitor
*periprocedural anticoagulation:—UFH, enoxaparin or bivalirudin.
**glycoprotein IIb/IIIa inhibitor may also be indicated.
Fibrinolytic therapy :
meds
aboriginals?
complications
Alteplase OR Reteplase OR Tenecteplase
Aboriginal Australians have high prevalence of IgG anti-streptokinase Ab, making Streptokinase inappropriate for thrombolytic therapy
1) should also be given a parenteral anticoagulant (enoxaparin or UFH). Bleeding can occur following treatment with a fibrinolytic drug and a parenteral anticoagulant.
2) .Significant arrhythmias including ventricular fibrillation can occur after reperfusion with fibrinolytic therapy.
Fibrinolytic therapy-CI
Absolute contraindications
- any prior intracranial haemorrhageknown structural cerebral vascular lesion (egAV malformation)
- *known malignant intracranial neoplasm (primary or metastatic)
- *ischaemic stroke within 3 months, except acute ischaemic stroke within 4.5 hours
- *suspected aortic dissection
- *active bleeding or bleeding diathesis (excluding menses)
- *significant closed head or facial trauma within 3 months
NSTEACS -Management
antiplatelet therapy and consider treatment with parenteral anticoagulant therapy, beta-blocker therapy, glycoprotein IIb/IIIa inhibitors and invasive management.
*Fibrinolytic therapy is NOT used to treat NSTEACS
Clinical trials have demonstrated the benefit of early invasive management for NSTEACS -coronary angiography and revascularisation[iestenting or bypass surgery]).
very high risk—recommended within 2 hours of admissionhigh risk—recommended within 24 hours of admission*intermediate risk—recommended within 72 hours of admission
Long-term management of ACS
antiplatelet therapy,
a statin,
*a beta blocker
*an ACEI.
*~Oral anticoagulation may be needed for patients with complications associated with myocardial infarction, such as mural thrombus or atrial fibrillation.
Dual antiplatelet therapyAspirin (75-150 mg) + a P2Y12 inhibitor[clopidogrel, prasugrel, ticagrelor])
For patients who have had a coronary stent inserted, dual antiplatelet therapy is** usually recommended for 12 months after an ACS**.Dual antiplatelet therapy for less than 12 months may be appropriate for patients at high risk of bleeding, and longer than 12 months may be appropriate for selected patients at high risk of recurrent ischaemicevents.When stopping dual antiplatelet therapy, stop the P2Y12 inhibitor and continue aspirin indefinitely.If aspirin is contraindicated, consider indefinite therapy with a P2Y12 inhibitor alone.
DAPT and surgery
months. of therapy
at least 6 weeks (ideally 3 months) following angioplasty with BMS
12 months after DES,
Post MI complications
1stday: V.Fibanytime within 24hrs and especially within 1hr and Heart failure
*2-4 days: **
*Arrythmia -Most** common
*Pericarditis -when occurring post MI, Aspirinis the treatment of choice and not other NSAID
*5-10 days:
*LV wall rupture (acute pericardial tamponade)
*Papillary muscle rupture with severe MR
Weeks to months**:
**Dressler’s syndrome occurs 2 -10 weeks post MI -autoimmune process with fever, pericarditis, pleural effusion, leucocutosis, incESR. Rx of choice is Aspirin if the cause is post MI.
*CHF, arrythmia, persistantST elevation, MR, thrombus formation
most common arrhythmia in the course of MI ?>
Ventricular tachicardia
Classification of CHF
Heart failure with reduced ejection fraction (HFrEF
LVEF <50%
Impaired ventricular contraction
Heart failure with preserved ejection fraction (HFpEF)
LVEF >50%
impairment of left ventricular filling
Diastolic CHF definition
and basic tx
Impairment of left ventricular filling with preserved systolic function
inotropic agents such as calcium-channel blockers (verapamil or diltiazem) and beta blockers.
If possible, avoid diuretics (except for congestion), digoxin, nitrates/vasodilators and nifedipine. Excessive diuresis from overzealous diuretic therapy can cause severe consequences for cardiac output. ACE inhibitors can be used with caution.
Systolic CHF most important cause?
IHD
CHF: = Symptom most common
signs
prognosis
EXERTIONAL DYSPNEA earliest and most common symptom
Prognosis of systolic HF can be predicted by JVP and S3 sound. Elevated JVP and presence of S3 indicates poor prognosis.
CHF: Pathophysiology
CHF
investigation
INITIAL
+
DIAGNOSTIC
1.CXR - cardiomegalia, pulmonary vesels etc
ECG not diagnostic but can help found out the cause.
DIAGNOSTIC
- echocardiograma EF <50% and ventricular dilatation **
B-type Natriuretic peptide >400
**if the diagnosis is unclear and an echocardiogram cannot be arranged in a timely fashion, then measurement of plasma B-type natriuretic peptide (BNP) or N-terminal pro-BNP levels improves diagnostic accuracy. It is highly sensitive although less specific for active CHF)*
The New York Heart Association (NYHA) functional classification
Mx of CHF
initial therapy
- includes a combination of diuretic therapy (as need to treat volume overload),
- an angiotensin system blocker (ACE inhibitor, or single agent ARB),
- beta blocker
In patients with a decompensated heart failure which was previously controlled :
initial assessment of volume status.
1.If hypervolemic -First step is volume reduction using loop diuretic such as furosemide, bumetanide or torsemide. It is also important to start patient with ACEIs (or ARBs IF ACEIS is not tolerated).
2.If euvolemic -an ACEI (or ARB) + a BB is the management of choice.Aldosterone antagonist (Spironolactopne) is used in euvolemic pts who have GFR >30ml/min and serum K level of <5mmol/lit with close monitoring of potassium levels
3.When euvolemic after hypervolemic -add a cardio selective BB
*** BB should only be started in pts who do NOT have crackles and no more than minimal peripheral edema. ~ BB is contraindicated in volume overload
**Digoxinis indicated with EF <35%. It should be added only after maximally tolerated dose of BB. It is also the initial management of pts with AF and decompensated HF
**
Hypervolemic state:
Inc JVP
*Inc weight
*Dyspnea
*Crackles
*More than minimal peripheral edema
*Elevated BNP
*Hepatomegaly, ascites or anasarca in severe cases
Acute pulmonary edema/congestion
symptoms
inv
Tx:
s/s : dyspnea, bibasal coarse crackles
investigation: CXR
TX: LMNOP
-Lasix -IV furosemide is one of the the initial step.
Morphine** -decreases sympathetic tone causes vasodilation and reduction of preload
**Nitrates-GTN reduces preload
Oxygen** -cannula, Hudson mask; CPAP, BiPAP for reducing venous return and preload
**Position( upright)
Hypertrophic cardiomyopathy
Causes:
*HTN
Aortic stenosis
HOCM
*O/E: *S4 gallop, Systolic murmur of MRSystolic murmur radiating to axilla due to LVTO
*Initial inv: *CXR -left atrial enlargement secondary to mitral regurgitation
*ECG (signs of LVH)
*Diagnostic inv : Echo-shows asymmetrical thickened septum, dynamic obstruction of blood flow, valvular lesions
Hypertrophic obstructive cardiomyopathy (HOCM)
TREATMENT
*is a congenital form, inheritedas an autosomal dominant train in 50% of HOCM pts.
Significant cause of sudden cardiac death in young people, including athletes.
**Positive family history **for sudden death at young age.
*Sudden loss of consciousnessin a young person while on exertion is most likely due to arrhythmia or HOCM
-
INITIAL=
BETABLOCKERS
CCB = DILTIAZEM / VERAPAMILO
->
implantable defibrilator if there is syncope
surgery severe cases-septoplastia
AVOID DIGITALIS, DIURETICS, VASODILATORS, EXCERSICE!
Bradyarrhythmias when TX?
Bradyarrhythmias should only be treated if they are causing significant haemodynamiccompromise